| Quality assessment | Number of patients | Effect | Quality | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Labetalol | Methyldopa | Relative (95% CI) | Absolute | ||
| Stillbirth | ||||||||||||
| 1 (Moore 1982) | randomised trials | very serious1 | no serious inconsistency | serious2 | no serious imprecision | none |
0/38 (0%) |
0/34 (0%) | not calculable | not calculable | VERY LOW | CRITICAL |
| Neonatal death | ||||||||||||
| 1 (Moore 1982) | randomised trials | very serious1 | no serious inconsistency | serious2 | very serious3 | none |
2/38 (5.3%) |
0/34 (0%) | RR 4.49 (0.22 to 90.30)6 | - | VERY LOW | CRITICAL |
| Small for gestational age | ||||||||||||
| 2 (Moore 1982, Sibai 1990) | randomised trials | very serious1 | no serious inconsistency | serious2 | very serious3 | none |
20/124 (16.1%) |
21/122 (17.2%) | RR 0.89 (0.53 to 1.49) | 19 fewer per 1000 (from 81 fewer to 84 more) | VERY LOW | CRITICAL |
| Birth weight (grams) (Better indicated by higher values) | ||||||||||||
| 1 (Moore 1982) | randomised trials | very serious1 | no serious inconsistency | serious2 | no serious imprecision | none | 38 | 34 | - | MD 7 higher (363.32 lower to 377.32 higher) | VERY LOW | IMPORTANT |
| Gestational age at birth (weeks) (Better indicated by higher values) | ||||||||||||
| 1 (Moore 1982) | randomised trials | very serious1 | no serious inconsistency | serious2 | no serious imprecision | none | 38 | 34 | - | MD 0.1 higher (1.2 lower to 1.4 higher) | VERY LOW | IMPORTANT |
| Admission to neonatal unit | ||||||||||||
| 1 (Moore 1982) | randomised trials | very serious1 | no serious inconsistency | serious2 | very serious3 | none |
19/38 (50%) |
16/34 (47.1%) | RR 1.06 (0.66 to 1.71) | 28 more per 1000 (from 160 fewer to 334 more) | VERY LOW | IMPORTANT |
| Maximum sBP after entry (mmHg) (Better indicated by lower values) | ||||||||||||
| 1 (Moore 1982) | randomised trials | very serious1 | no serious inconsistency | serious2 | serious4 | none | 38 | 34 | - | MD 2.7 higher (5.82 lower to 11.22 higher) | VERY LOW | CRITICAL |
| Maximum dBP after entry (mmHg) (Better indicated by lower values) | ||||||||||||
| 1 (Moore 1982) | randomised trials | very serious1 | no serious inconsistency | serious2 | serious5 | none | 38 | 34 | - | MD 0.9 lower (5.99 lower to 4.19 higher) | VERY LOW | CRITICAL |
| Onset of labour (induction) | ||||||||||||
| 1 (Moore 1982) | randomised trials | very serious1 | no serious inconsistency | serious2 | very serious3 | none |
20/38 (52.6%) |
14/34 (41.2%) | RR 1.28 (0.77 to 2.11) | 115 more per 1000 (from 95 fewer to 457 more) | VERY LOW | IMPORTANT |
| Mode of birth (C-section) | ||||||||||||
| 2 (Moore 1982, Sibai 1990) | randomised trials | very serious1 | no serious inconsistency | serious2 | very serious3 | none |
49/124 (39.5%) |
51/122 (41.8%) | RR 0.93 (0.69 to 1.26) | 29 fewer per 1000 (from 130 fewer to 109 more) | VERY LOW | IMPORTANT |
The quality of the evidence was downgraded by 2 levels due to an unclear risk of random sequence generation, allocation concealment, performance and selection bias, and selective reporting
The quality of the evidence was downgraded by 1 level as 34.8% of participants did not present with chronic hypertension
The quality of the evidence was downgraded by 2 levels as the 95% CI crossed 2 default MID thresholds (0.8 and 1.25)
The quality of the evidence was downgraded by 1 level as the 95% CI crossed 1 MID threshold (14.9 × +/− 0.5 = +/− 7.45)
The quality of the evidence was downgraded by 1 level as the 95% CI crossed 1 default MID threshold (9.1 × +/− 0.5 = +/−4.55)
The corresponding absolute risk was not calculated as there were no events reported in the control arm.
From: Evidence review for interventions for chronic hypertension
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.